Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01820572 · ClinicalTrials.gov registry record · Phase 3
A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 446
- Enrollment target
NCT01820572: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT01820572 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 446 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01820572, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 446 participants
- Enrollment target
Study Summary
The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-60 months after kidney transplant.
Primary Outcome
Percentage of participants who survive with a functional graft at 24 months post-randomization
Interventions
- DRUG Tacrolimus
- DRUG Cyclosporine
- DRUG Belatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 446 participants |
| Start Date | 2013-03-27 |
| Est. Completion | 2019-10-24 |
| Phase | Phase 3 |
What the finished NCT01820572 record still lists
NCT01820572 is an interventional study that assigns participants to a tested intervention. The registered 446 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 3 interventions - of which Tacrolimus is the first listed.
NCT01820572 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01820572 about?
NCT01820572 is a clinical study titled "A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based". The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-60 months after kidney transplant.
What is the current status of trial NCT01820572?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 446 participants. The study started on 2013-03-27. Estimated completion is 2019-10-24.
What interventions are being tested in trial NCT01820572?
The interventions under investigation include: Tacrolimus (DRUG), Cyclosporine (DRUG), Belatacept (DRUG).
Who is sponsoring clinical trial NCT01820572?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01820572's enrollment target sits among peer trials
446 864th of 2000 higher than 1,137 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04065399 · 447 participants · Phase 1
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- NCT01280994 · 445 participants · Phase 2
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
- NCT03504800 · 445 participants
OCT in Diagnosis of Irregular Corneas
- NCT04751435 · 445 participants · NA
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI